The US drug company Johnson and Johnson was told to pay $ 8 billion (£ 6.6 billion) in criminal damages to a man for allegedly that he had not been advised that the antipsychotic drug could lead to breast growth.
A Philadelphia jury awarded the prize to 26-year-old Nicholas Murray, whose case is one of thousands hanging in the state.
His lawyers claimed that J&J Janssen's subsidiary was making "profits."
J&J would appeal the decision, which he said was "disproportionate."
The US giant is also facing legal challenges over vaginal mesh implants and baby powder, which is said to be tainted with asbestos, in addition to the ongoing a legal battle over his role in the drug crisis
In August, Johnson and Johnson were ordered to pay $ 572 million after an Oklahoma judge ruled the company was contributing to the state's opioid epidemic by campaigning for counterfeit and dangerous sales.
Most recently, she reached a $ 20.4 million agreement with two counties in Ohio before the opioid crisis process, scheduled for later this month, begins.
In the Risperdal trial, Mr Murray stated that he developed breasts after his doctor prescribed the drug in 2003, when he was diagnosed with autism spectrum disorder.
Risperdal is approved for the treatment of schizophrenia and bipolar disorder, but physicians may lawfully prescribe the drug for any condition they deem necessary.
The company said it was confident the decision would be overturned and said the court prevented their legal team from presenting "key evidence" on drug labeling.
A state court of appeals upheld the sentence last year, but reduced it to $ 680,000.